Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALKS
BUYAlkermes plc · Healthcare · Ireland · $8.8B · Avg Vol: $120M/d
COMPANY DESCRIPTION
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines for central nervous system (CNS) disorders, including schizophrenia, bipolar disorder, and addiction. The company differentiates itself through its proprietary drug delivery technologies and a pipeline of differentiated psychiatric and neurological products. Its specialized focus and R&D capabilities provide a competitive moat in a challenging therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.7B | 1.6B | 1.5B | 9.9% | 1.6B | 1.8B | 1.9B | 13.1% |
| EPS | -0.97 | 2.14 | 2.22 | 1.47 | -17.1% | 0.88 | 0.86 | 1.15 | -11.6% |
| Shares | 164.4M | 167.0M | 162.2M | 165.6M | +0.7% | 166.7M | — | — | — |
| Debt | 379.4M | 372.2M | 75.5M | 70.0M | -43.1% | 1.6B | — | — | — |
| Equity | 1.0B | 1.2B | 1.5B | 1.8B | 20.3% | — | — | — | — |
| Op CF | 21.0M | 401.4M | 439.1M | 520.8M | 191.4% | 256.2M | — | — | — |
| Inv CF | -64.5M | 53.4M | -111.3M | 295.5M | — | — | — | — | — |
| Fin CF | -1.6M | -289.7M | -494.1M | 12.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALKS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALKS | Alkermes plc(you) | $8.8B | 78 | BUY |
| PRGO | Perrigo Company plc | $1.4B | 51 | HOLD |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
| ICLR | ICON Public Limited Company | $12.8B | 57 | HOLD |
| UPR.IR | Uniphar plc | $1.4B | 71 | BUY |
| 2M6.DE | Medtronic plc | $104.4B | 75 | BUY |
| GHRS | GH Research PLC | $1.9B | 34 | SELL |
| 0RGI.L | Cosmo Pharmaceuticals N.V. | $1.8B | 17 | STRONG SELL |
| COPN.SW | Cosmo N.V. | $1.4B | 19 | STRONG SELL |
| AMRN | Amarin Corporation plc | $284M | 45 | HOLD |
Peer medians: ROE 0.7% · P/E 22.9x · Gross margin 48.5%